Skip to main content
. Author manuscript; available in PMC: 2010 Oct 20.
Published in final edited form as: Int J Hyperthermia. 2010;26(5):499–513. doi: 10.3109/02656731003623590

Figure 4.

Figure 4

DOX-loaded LTSL are administered intravenously (A). The LTSL release their content into the tumour plasma space as soon as the required temperature (~40°C) is reached (B). The released DOX can now cross the vessel wall (C) into the tumour tissue where the DOX can diffuse (D) and intracellular uptake (E) takes place. Some drug exits the tumour plasma space due to perfusion (F).